[go: up one dir, main page]

SG10201913920PA - Modulation of splenocytes in cell therapy - Google Patents

Modulation of splenocytes in cell therapy

Info

Publication number
SG10201913920PA
SG10201913920PA SG10201913920PA SG10201913920PA SG10201913920PA SG 10201913920P A SG10201913920P A SG 10201913920PA SG 10201913920P A SG10201913920P A SG 10201913920PA SG 10201913920P A SG10201913920P A SG 10201913920PA SG 10201913920P A SG10201913920P A SG 10201913920PA
Authority
SG
Singapore
Prior art keywords
splenocytes
modulation
cell therapy
therapy
cell
Prior art date
Application number
SG10201913920PA
Inventor
W Mays Robert
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Publication of SG10201913920PA publication Critical patent/SG10201913920PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
SG10201913920PA 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy SG10201913920PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33400110P 2010-05-12 2010-05-12
US201161440617P 2011-02-08 2011-02-08

Publications (1)

Publication Number Publication Date
SG10201913920PA true SG10201913920PA (en) 2020-03-30

Family

ID=44914707

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913920PA SG10201913920PA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG10201503700WA SG10201503700WA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG2012083192A SG185526A1 (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201503700WA SG10201503700WA (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy
SG2012083192A SG185526A1 (en) 2010-05-12 2011-05-12 Modulation of splenocytes in cell therapy

Country Status (8)

Country Link
US (3) US9937208B2 (en)
EP (1) EP2568991B3 (en)
AU (1) AU2016201524B2 (en)
CA (2) CA2798895A1 (en)
DK (1) DK2568991T6 (en)
IL (3) IL222942B (en)
SG (3) SG10201913920PA (en)
WO (1) WO2011143415A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2014089268A2 (en) 2012-12-06 2014-06-12 StemBios Technologies, Inc. Lgr5+ somatic stem cells
CN105338989B (en) 2013-04-12 2022-04-08 赛维里奥·拉弗朗切西卡 Improvements in organs for transplantation
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
HK1232131A1 (en) * 2014-11-19 2018-01-05 干细胞生物科技公司 Somatic stem cells for treating bone defects
NZ745530A (en) 2016-01-21 2023-03-31 Abt Holding Co Stem cells for wound healing
CN110099921A (en) * 2016-12-23 2019-08-06 干细胞生物科技公司 Somatic stem cell for reducing IL-6 level purposes
CN115666599A (en) * 2020-04-23 2023-01-31 Abt控股公司 Treatment of virus-induced acute respiratory distress syndrome

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPH0628570B2 (en) 1986-02-13 1994-04-20 雪印乳業株式会社 Method and device for manufacturing capsule body
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
AU650616B2 (en) 1988-09-21 1994-06-30 Animal Biotechnology Cambridge Limited Derivation of pluripotential embryonic cell lines from domestic animals
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2882992A (en) 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
ES2178654T3 (en) 1993-08-12 2003-01-01 Neurotech Sa IMMONO-ISOLATED BIOCOMPATIBLE CAPSULES CONTAINING GENETICALLY ALTERED CELLS FOR THE SUPPLY OF BIOLOGICALLY ACTIVE MOLECULES.
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
DE69831957T3 (en) 1997-07-14 2009-07-23 Osiris Therapeutics, Inc. HEART MUSCLES GENERATION USING MESENCHYMAL STEM CELLS
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
CA2315265A1 (en) 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DK1066052T3 (en) 1998-03-18 2006-06-12 Osiris Therapeutics Inc Mesenchymal stem cells for the prevention and treatment of immune responses in transplants
ATE246938T1 (en) 1998-04-03 2003-08-15 Osiris Therapeutics Inc APPLICATION OF MESENCHYMAL STEM CELLS AS IMMUNOSUPPRESSANTS
AU758073B2 (en) 1998-11-09 2003-03-13 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
EP1129176A4 (en) 1998-11-09 2002-10-30 Es Cell Int Pte Ltd Embryonic stem cells
CA2347914A1 (en) 1998-11-13 2000-05-25 Osiris Therapeutics, Inc. Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050169896A1 (en) 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
EP1200101A4 (en) 1999-07-29 2003-02-05 Steven Baranowitz Methods for transdifferentiation of body tissues
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
JP5398941B2 (en) * 1999-08-05 2014-01-29 エイビーティー ホールディング カンパニー Pluripotent adult stem cell and method for isolating the same
WO2002064748A2 (en) 2001-02-14 2002-08-22 Furcht Leo T Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2005113748A2 (en) 2004-04-21 2005-12-01 Regents Of The University Of Minnesota Mapc generation of lung tissue
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
WO2005056026A1 (en) 2003-12-04 2005-06-23 Regents Of The University Of Minnesota Compositions and methods for the treatment of lysosomal storage disorders
WO2001021766A2 (en) 1999-09-23 2001-03-29 Cell Science Therapeutics Methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
EP1218489B1 (en) 1999-09-24 2009-03-18 Cybios LLC Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
DE60041821D1 (en) 1999-09-24 2009-04-30 Cybios Llc PLURIPOTENT EMBRYONAL STEM CELL-SIMILAR CELLS, COMPOSITIONS, AND ITS CONDITIONS
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20010046489A1 (en) 1999-12-06 2001-11-29 Habener Joel E. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
ES2300320T3 (en) 2000-02-26 2008-06-16 Artecel, Inc. PLURIPOTENT MOTHER CELLS GENERATED FROM STROMA CELLS DERIVED FROM ADIPOSE TISSUE AND ITS USES.
EP2298867A3 (en) 2000-06-20 2013-01-16 ES Cell International Pte Ltd. Method of controlling differentiation of embryonic stem (ES) cells by culturing ES cells in the presence of bmp-2 pathway antagonists
EP1176189A1 (en) 2000-07-21 2002-01-30 Fornix Biosciences N.V. Stem cell-like cells
US20020098167A1 (en) 2000-07-31 2002-07-25 Piero Anversa Methods and compositions for the repair and/or regeneration of damaged myocardium
GB0026252D0 (en) 2000-10-26 2000-12-13 Univ Edinburgh Pluripotential stem cells
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2522890T3 (en) 2000-12-06 2014-11-19 Anthrogenesis Corporation Method to collect placental stem cells
IL157350A0 (en) 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
KR100449141B1 (en) 2001-04-19 2004-09-21 (주)라이프코드 Method for differentiating a mesenchymal stem cell into neural cells
JP2004531256A (en) 2001-04-24 2004-10-14 バクシュ，ドロレス Progenitor cell populations, their proliferation and the growth of non-hematopoietic cell types and tissues therefrom
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
BR0212098A (en) 2001-08-23 2004-08-03 Reliance Life Sciences Pvt Ltd Internal cell mass isolation method for the establishment of human embryonic stem cell lines (hesc)
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
DE60236016D1 (en) * 2001-12-21 2010-05-27 Mount Sinai Hospital Corp CELLULAR COMPOSITIONS AND METHOD FOR THE PREPARATION AND USE THEREOF
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
EP1478734A4 (en) 2002-01-25 2006-04-05 Genzyme Corp Serum-free media for chondrocytes and methods of use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
GB0221481D0 (en) 2002-09-16 2002-10-23 Richards John M Grip for hand held instruments
WO2004050859A2 (en) 2002-11-27 2004-06-17 Regents Of The University Of Minnesota Homologous recombination in multipotent adult progenitor cells
CA2521469A1 (en) 2003-04-04 2004-10-21 University Of Rochester Identification of novel nogo-receptors and methods related thereto
US20040235165A1 (en) 2003-05-19 2004-11-25 Darwin Prockop In vitro differentiation of adult stem cells
US8192348B2 (en) 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
WO2005003320A2 (en) 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
ITRM20030376A1 (en) 2003-07-31 2005-02-01 Univ Roma PROCEDURE FOR THE ISOLATION AND EXPANSION OF CARDIOC STAMIN CELLS FROM BIOPSIA.
CN1845987A (en) 2003-08-29 2006-10-11 明尼苏达大学董事会 Kidney derived stem cells and methods for their isolation, differentiation and use
US8124072B2 (en) * 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
DK1725656T3 (en) 2004-03-05 2014-01-13 John E Davies Serum-free suspension culture system for mesenchymal progenitor cells
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
WO2006047593A2 (en) * 2004-10-22 2006-05-04 University Of South Florida Method of potentiating inflammatory and immune modulation for cell and drug therapy
WO2006047743A2 (en) 2004-10-26 2006-05-04 Regents Of The University Of Minnesota Swine multipotent adult progenitor cells
WO2006086639A1 (en) 2005-02-10 2006-08-17 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
AU2005331534B2 (en) 2005-05-05 2011-12-08 Regents Of The University Of Minnesota Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues
WO2006121428A1 (en) 2005-05-05 2006-11-16 Regents Of The University Of Minnesota Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
US20080194021A1 (en) 2005-07-29 2008-08-14 Mays Robert W Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
CN101310012B (en) 2005-10-14 2012-05-09 明尼苏达大学董事会 Differentiation of non-embryonic stem cells into cells with pancreatic phenotype
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
CN104027359A (en) 2006-01-23 2014-09-10 阿特西斯公司 MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment
WO2008020657A1 (en) * 2006-08-14 2008-02-21 Seoul National University Industry Foundation Acquired pluripotency through ovarian niche
EP2087101A2 (en) 2006-11-24 2009-08-12 Regents of the University of Minnesota Endodermal progenitor cells
JP2008307007A (en) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
AU2009205886B2 (en) 2008-01-18 2015-08-27 Katholieke Universiteit Leuven Stem cell aggregates and methods for making and using
CA2723765A1 (en) * 2008-05-08 2009-11-12 Coretherapix Slu Multipotent adult stem cell population
WO2010028249A1 (en) 2008-09-04 2010-03-11 Abt Holding Company Use of stem cells to prevent neuronal dieback
WO2010049752A1 (en) 2008-10-31 2010-05-06 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
US20110020293A1 (en) 2009-07-21 2011-01-27 Abt Holding Company Use of Stem Cells to Reduce Leukocyte Extravasation
EP2456860B1 (en) 2009-07-21 2018-09-05 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
CA2781194A1 (en) 2009-11-19 2011-05-26 Regents Of The University Of Minnesota Reducing inflammation using cell therapy
KR101900507B1 (en) * 2010-02-25 2018-09-19 에이비티 홀딩 컴퍼니 Modulation of angiogenesis
WO2011106521A1 (en) * 2010-02-25 2011-09-01 Abt Holding Company Modulation of macrophage activation
WO2011106476A1 (en) 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
US20110206647A1 (en) 2010-02-25 2011-08-25 Abt Holding Company Modulation of Angiogenesis
US9914223B2 (en) 2010-02-26 2018-03-13 Little Caesar Enterprises, Inc. Automated pizza assembly system
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
WO2012027474A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
JP5364147B2 (en) 2011-01-17 2013-12-11 シナノケンシ株式会社 Magnet and method for manufacturing magnet
US9388388B2 (en) 2011-01-31 2016-07-12 Katholieke Universiteit Leuven Methods for making cells with an extra-embryonic endodermal precursor phenotype
PL2718416T3 (en) 2011-06-06 2020-05-18 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
CN105338989B (en) 2013-04-12 2022-04-08 赛维里奥·拉弗朗切西卡 Improvements in organs for transplantation
US20140322135A1 (en) 2013-04-30 2014-10-30 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
US20160069903A1 (en) * 2014-09-10 2016-03-10 Fundació Institute De Ciències Foròniques Method for detecting cells
WO2016177859A1 (en) 2015-05-05 2016-11-10 Katholieke Universiteit Leuven (Kuleuven) Improved methods for pancreatic islet transplantation
CA3012009A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
NZ745530A (en) 2016-01-21 2023-03-31 Abt Holding Co Stem cells for wound healing

Also Published As

Publication number Publication date
US9937208B2 (en) 2018-04-10
DK2568991T3 (en) 2018-06-18
IL222942A0 (en) 2012-12-31
SG10201503700WA (en) 2015-06-29
AU2016201524B2 (en) 2017-06-08
EP2568991A1 (en) 2013-03-20
CA2798895A1 (en) 2011-11-17
IL274687B (en) 2021-09-30
IL274687A (en) 2020-06-30
EP2568991B3 (en) 2018-11-28
IL284501A (en) 2021-08-31
US20110293642A1 (en) 2011-12-01
DK2568991T6 (en) 2019-03-18
AU2011253014A1 (en) 2012-12-06
SG185526A1 (en) 2012-12-28
US20200390821A1 (en) 2020-12-17
IL222942B (en) 2020-06-30
EP2568991A4 (en) 2013-11-06
WO2011143415A1 (en) 2011-11-17
CA3128483A1 (en) 2011-11-17
US10758570B2 (en) 2020-09-01
US20180250342A1 (en) 2018-09-06
EP2568991B1 (en) 2018-03-21
AU2016201524A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
IL284501A (en) Modulation of splenocytes in cell therapy
IL228031B (en) Aav-vectors for use in gene therapy of choroideremia
EP2622713A4 (en) System and method to manage power usage
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2552323A4 (en) Combination therapy
GB201100180D0 (en) Tumour cell and tissue culture
EP2563426A4 (en) High shear application in medical therapy
PL2659004T3 (en) Modulation of dynein in skin
IL220610A0 (en) Methods of rpoviding weight loss therapy in patients with major depression
IL226805B (en) Cd89 activation in therapy
GB201017820D0 (en) Cells and devices
SG11201502214PA (en) Adipose tissue cells
EP2576777A4 (en) Ideotypically modulated pharmacoeffectors for selective cell treatment
GB201005394D0 (en) Therapy
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
HUE044196T2 (en) Cell therapy
TWM387549U (en) Solar energy massage slippers
GB201216933D0 (en) Adipose tissue cells
GB201216936D0 (en) Adipose tissue cells
AU2010900626A0 (en) Improvements in or Relating to Power Supplies
GB201007318D0 (en) Improvements in or relating to power adapters
GB201102228D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy